Clinical Trials Browser

Phase 1 × OTHER × Neuromyelitis Optica × Clear all

NCT07526493 2026-04-13

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Multiple Sclerosis, Myasthenia Gravis, Myositis, Neuromyelitis Optica, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT06249438 2025-07-25

CAR-AID

Phase 1 Recruiting

30 enrolled

Lupus Erythematosus, Systemic, Multiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica, Scleroderma, Systemic

NCT02276963 2019-06-06

Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses

Phase 1 Completed

6 enrolled 9 charts

Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis

NCT00501748 2011-09-27

Safety and Tolerability of Rituximab in Neuromyelitis Optica

Phase 1 Completed

20 enrolled

Myelitis, Transverse, Neuromyelitis Optica